PDGFB and breast carcinoma: One interpretation of these results is that disruption of PDGFR-β/PDGF-B signaling may be important to block activation of STAT3 signaling, due to the effects of imatinib on inhibition of PDGFR phosphorylation in breast cancer (Figure 5B) [48].